Related Experiment Video
Updated: Jun 16, 2026
Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines
Published on: October 30, 2018
DNA vaccines against cancer come of age
Freda K Stevenson1, Christian H Ottensmeier, Jason Rice
1Cancer Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Southampton, UK. fs@soton.ac.uk
Abstract:
Genetic technology allows construction of DNA vaccines encoding selected tumor antigens together with molecules to direct and amplify the desired effector pathways. Their enormous promise has been marred by a problem of scaling up to human subjects. This is now largely overcome by electroporation, which increases both antigen expression and the inflammatory milieu. While the principles of vaccine design can be developed in mouse models, the real operative test is in the clinic, using patients in temporary remission. Monitoring of induced immunity, although commonly limited to blood, is providing objective qualitative and quantitative data on T-cell and antibody responses. Prolongation of remission is the goal and an activated immune system should achieve this.
Insights
DNA vaccines offer promising cancer treatment by stimulating immune responses. Electroporation enhances their effectiveness in patients, potentially prolonging remission by activating the immune system.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- DNA vaccines encode tumor antigens to direct immune responses.
- Scaling DNA vaccines for human use was a challenge.
- Electroporation improves antigen expression and immune stimulation.
Purpose of the Study:
- To evaluate the clinical efficacy of DNA vaccines enhanced by electroporation.
- To assess the ability of these vaccines to prolong remission in cancer patients.
Main Methods:
- Development of DNA vaccines encoding tumor antigens and immune-directing molecules.
- Application of electroporation to enhance vaccine delivery and immunogenicity.
- Clinical trials in patients with temporary remission.
- Monitoring of T-cell and antibody responses via blood analysis.
Main Results:
- Electroporation overcomes previous scaling limitations for human application.
- Monitoring reveals objective, quantifiable T-cell and antibody responses.
- The technology shows potential for clinical application in cancer therapy.
Conclusions:
- DNA vaccines combined with electroporation represent a promising strategy for cancer immunotherapy.
- Monitoring immune responses provides valuable data for vaccine optimization.
- The ultimate goal is to prolong remission through immune system activation.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy